Pediatric Neuroblastoma Treatment Market Outlook 2026-2030

2026-04-02 23:36:37

Abstract generation in progress

The pediatric neuroblastoma treatment market is experiencing substantial growth, projected to reach $3.13 billion by 2030 from $2.02 billion in 2025, driven by enhanced R&D in targeted therapies, increased use of CAR T-cell and monoclonal antibodies, and personalized medicine. Key drivers include a rising number of neuroblastoma cases globally and advancements in diagnostic and screening technologies. Leading companies like United Therapeutics and Pfizer are innovating with antibody-based approaches, and North America currently leads the market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.